Intervention

acarbose

ClinicalTrials.gov intervention label

Clinical trials8

Recruiting0

Common conditions9

Lead sponsors shown7

Clinical trials

8 shown

Comparison of Standard vs Higher Starting Dose of Insulin Glargine in Chinese Patients With Type 2 Diabetes (Glargine Starting Dose)NCT02836704 · 2016-09-09

A Study to Assess the Efficacy and Safety of ASP1941 in Asian Subjects With Type 2 Diabetes MellitusNCT01514838 · 2012-04-23

Remission Evaluation of Metabolic Interventions in Type 2 Diabetes (REMIT Pilot Trial)NCT01181674 · 2011-01-01

Impact of Acarbose on Abnormal Glucose Regulation in Patients With Coronary Artery Disease (AAA Trial)NCT00858676 · 2009-04-01

The Effects of Nateglinide and Acarbose on the Post-Prandial Glucose Control in Type 2 Diabetic PatientsNCT00437918 · 2007-01-01

Effects of Acarbose on Endothelial Function After a Mixed Meal in Newly Diagnosed Type 2 DiabetesNCT00551954 · 2006-07-01

AI(I)DA Acarbose and the Subclinical InflammationNCT00558883 · 2005-01-01

Metabolic Syndrome Risk Factor in IGT: STOP-NIDDM TrialNCT00629213

Common conditions

Type 2 Diabetes Mellitus3 Diabetes Mellitus2 Coronary Artery Disease1 Diabetes Mellitus, Type 21 Impaired Glucose Tolerance1 Metabolic Syndrome1 Subclinical Inflammation1 Type 2 Diabetes1 Type II Diabetes Mellitus1

Leading sponsors

GWT-TUD GmbH2 Aichi Gakuin University1 Astellas Pharma Inc1 Inje University1 Population Health Research Institute1 Sanofi1 Technische Universität Dresden1

Trial status mix

COMPLETED6

TERMINATED1

UNKNOWN1

Phase mix

PHASE34

PHASE44

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.